Celyad Oncology announces receipt of Nasdaq notice
April 04, 2023 16:01 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, April 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric...
Celyad Oncology appoints Georges Rawadi as its new CEO
March 24, 2023 02:00 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, March 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric...
Celyad Oncology reports full year 2022 financial results and recent business highlights
March 23, 2023 17:01 ET
|
Celyad Oncology SA
Starting in 2023, Celyad Oncology is now entirely focused on its new business strategy with one clear objective: help to overcome the current limitations of CAR-T approaches. It plans to do this via...
Celyad Oncology to announce full year 2022 financial results and host conference call
March 17, 2023 17:01 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of...
Celyad Oncology announces non-cash impairment
March 15, 2023 02:00 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, March 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of...
REPEAT -- Celyad Oncology SA - Letter to Shareholders
March 01, 2023 01:00 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, March 01, 2023 (GLOBE NEWSWIRE) -- The following is a statement by Celyad Oncology: Dear Shareholder, 2022 has been a crossroad year for Celyad Oncology (the...
Celyad Oncology SA - Letter to Shareholders
February 28, 2023 11:16 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Feb. 28, 2023 (GLOBE NEWSWIRE) -- The following is a statement by Celyad Oncology: Dear Shareholder, 2022 has been a crossroad year for Celyad Oncology (the...
Celyad Oncology announces the publication of data from its Phase 1 THINK study of CYAD-01
February 09, 2023 01:00 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of...
Celyad Oncology provides fourth quarter 2022 business update and 2023 outlook
February 03, 2023 01:00 ET
|
Celyad Oncology SA
Celyad Oncology has implemented a strategic shift from an organization focused on clinical development to one fully harnessing the true potential of its proprietary technology platforms and...
Celyad Oncology provides an update on its strategic business model, continuing to focus on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property
December 21, 2022 01:00 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of...